biostudies-literatureUnknown13Fattizzo BMore than half of patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with complement fraction C5 inhibitors experience residual anemia and hemolysis. This is partly due to the persistent activation of the complement cascade upstream C5, resulting in C3 deposition on PNH erythrocytes and extravascular hemolysis in the reticuloendothelial system. Pegcetacoplan is the first proximal C3 inhibitor to be approved for PNH basing on favorable efficacy and safety data in both naïve and eculizumab treated PNH. Here we report the first Italian patient treated with pegcetacoplan in a named patient program. The patient suffered from hemolytic PNH associated with CALR+ myeloproliferative neoplasm and was heavily transfusion dependent despite eculizumab therapy. Treatment with pegcetacoplan Frontiers in immunology1060923https://www.ebi.ac.uk/biostudies/studies/S-EPMC9751407biostudies-literatureCase report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan.PMC9751407Versino FVercellati CFattizzo BArtuso SZaninoni ABarcellini WMarcello APMLfalseCase report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan.More than half of patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with complement fraction C5 inhibitors experience residual anemia and hemolysis. This is partly due to the persistent activation of the complement cascade upstream C5, resulting in C3 deposition on PNH erythrocytes and extravascular hemolysis in the reticuloendothelial system. Pegcetacoplan is the first proximal C3 inhibitor to be approved for PNH basing on favorable efficacy and safety data in both naïve and eculizumab treated PNH. Here we report the first Italian patient treated with pegcetacoplan in a named patient program. The patient suffered from hemolytic PNH associated with CALR+ myeloproliferative neoplasm and was heavily transfusion dependent despite eculizumab therapy. Treatment with pegcetacoplan 2022-01-01T00:00:00Z20222025-04-19T09:49:47.464Z2025-04-19T09:49:47.464ZS-EPMC97514073653207310.3389/fimmu.2022.1060923